Q2 2024 AtriCure Inc Earnings Call Transcript
Key Points
- AtriCure Inc (ATRC) achieved total revenue of $116 million, reflecting over 15% growth.
- The company generated nearly $8 million in positive adjusted EBITDA for the quarter.
- AtriCure Inc (ATRC) reached an exciting milestone with positive cash flow generation of over $8 million.
- The pain management franchise grew 25% in the second quarter of 2024.
- The company received FDA clearance for the AtriClip Flex Mini, a new generation device expected to achieve rapid adoption.
- Gross margin decreased by approximately 170 basis points compared to the second quarter of 2023.
- Total operating expenses increased by $12.8 million, or 15.7%, from the second quarter of 2023.
- The company experienced a slight decline in minimally invasive appendage management products.
- Interest in PFA catheters within certain hospital systems led to pressure in hybrid therapy results for the quarter.
- The company revised its full-year guidance to $456 million to $461 million, reflecting a lower contribution from US MIS ablation and MIS appendage management products.
Good afternoon and welcome to AtriCure's second quarter 2024 earnings conference call. This call is being recorded for replay purposes. (Operator Instructions) We will be facilitating a question and answer session following prepared remarks from AtriCure's management.
I would now like to turn the call over to Marissa Bych from the Gilmartin Group for a few introductory comments.
Great, thank you, operator. By now you should have received a copy of the earnings press release. If you have not received a copy, please call (513)644-4484 to have one emailed to you.
Before we begin today, let me remind you that the company's remarks include forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond AtriCure's control, including risks and uncertainties described from time to time in AtriCure's SEC filings. These statements include, but are not limited to, financial expectations and guidance, expectations regarding the potential
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
